

Human trials for Glenmark Pharma's pain drug

Glenmark Pharmaceuticals said on Thursday its experimental pain drug, dubbed GRC 27864, will enter human trials. The drug intends to be an improvement by removing gastrointestinal and cardiovascular side effects seen in currently approved pain-relief therapies. The company said it completed pre-clinical studies and filed an application for phase 1 studies with UKMHRA. Glenmark expects the phase 1 trial to be completed by January 2015.

Clinical trials / R&D